Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
2017 · The Lancet · 811 citations
https://doi.org/10.1016/s0140-6736(17)31585-4
I
Icíar Avilés-Olmos
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
66
Papers
4.0K
Citations
23
h-index
32
i10-index
Icíar Avilés-Olmos is an academic researcher from Magna Graecia University. The author has contributed to research in topics: Neurological disorders and treatments & Parkinson's Disease Mechanisms and Treatments & Health, Medicine and Society. The author has an h-index of 23, co-authored 57 publications.
ORCID: 0000-0002-1645-7406Papers by this author
worksExenatide and the treatment of patients with Parkinson’s disease
2013 · Journal of Clinical Investigation · 494 citations
https://doi.org/10.1172/jci68295
Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
2014 · Journal of Parkinson s Disease · 292 citations
https://doi.org/10.3233/jpd-140364
A genomic approach to therapeutic target validation identifies a glucose-lowering <i>GLP1R</i> variant protective for coronary heart disease
2016 · Science Translational Medicine · 118 citations
https://doi.org/10.1126/scitranslmed.aad3744
El correo electrónico en la consulta de Parkinson: ¿soluciones a un clic?
2016 · Neurología · 7 citations
https://doi.org/10.1016/j.nrl.2016.05.020
Targeting Metabolic Dysfunction in Parkinson’s Disease: The Role of GLP-1 Agonists in Body Weight Regulation and Neuroprotection
2025 · Current Diabetes Reports · 4 citations
https://doi.org/10.1007/s11892-025-01606-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat